ESTRO 2024 - Abstract Book

S4669

Physics - Optimisation, algorithms and applications for ion beam treatment planning

ESTR0 2024

4) Wang, W., Li, C., Qiu, R., Chen, Y., Wu, Z., Zhang, H., and Li, J. (2018). Modelling of cellular survival following radiation induced dna double-strand breaks. Scientific reports, 8(1):16202.

5) Stewart, Robert D. (2001). Two-lesion kinetic model of double-strand break rejoining and cell killing. Radiation research, 156.4: 365-378.

6) Battistoni, G., Boehlen, T., Cerutti, F., Chin, P. W., Esposito, L. S., Fasso, A., Ferrari, A., Lechner, A., Empl, A., Mairani, A., et al. (2015). Overview of the fluka code. Annals of Nuclear Energy,82:10–18.

7) Friedrich, T., Scholz, U., Elsasser, T., Durante, M., and Scholz, M. (2013). Systematic analysis of rbe and related quantities using a database of cell survival experiments with ion beam irradiation. Journal of radiation research, 54(3):494–514

8) Salgado Maldonado, S. and Russomando, A. (2022). Conversion of dose distribution to cell survival fraction through dna damage: A monte carlo study. Radiation Protection Dosimetry, 198(19):1462–1470.

9) Salgado Maldonado, S., Carabe A., Espinoza I., Galvez S., Valenzuela M.P., Russomando, A. (2023). Monte Carlo simulations of cell survival in proton SOBP. Physics in Medicine & Biology 68.19: 195024.

10) Wouters B. G., Skarsgard L.D., Gerweck L.E., Carabe A., Wong M., Durand E., Nielson D., Bussiere M.R., Wagner M., Biggs P., et al (2015). Radiobiological intercomparison of the 160 MeV and 230 MeV proton therapy beams at the harvard cyclotron laboratory and at massachusetts general hospital Radiat. Res. 183 174.

2186

Digital Poster

Dosimetric comparison of carbon ion and proton beam therapy for large primary renal cell cancer

Harshani Green 1,2,3 , Silvia Molinelli 4 , Pravesh Bhudia 3 , Orla Byrne 5 , Callum Gillies 3 , Viviana Vitolo 6 , Ester Orlandi 7 , Mario Ciocca 6 , Anita Mitra 8 , Vincent Khoo 1,2 1 Royal Marsden NHS Foundation Trust, Oncology, London, United Kingdom. 2 Institute of Cancer Research, Radiotherapy, London, United Kingdom. 3 University College London Hospitals NHS Foundation Trust, Proton Beam Therapy, London, United Kingdom. 4 Centro Nazionale di Adroterapia Oncologica, Physics, Pavia, Italy. 5 Royal Marsden NHS Foundation Trust, Physics, London, United Kingdom. 6 Centro Nazionale di Adroterapia Oncologica, Carbon ion and proton beam therapy, Pavia, Italy. 7 Centro Nazionale di Adroterapia Oncologica, Carbon ion and proton beam therapy, Pavia, United Kingdom. 8 University College London Hospitals NHS Foundation Trust, Oncology, London, United Kingdom

Purpose/Objective:

Stereotactic body radiotherapy (SBRT) for primary renal cell carcinoma (RCC) is now a recognised treatment option for inoperable patients[1]. Cancer-specific survival at 5-years is reported at 92%[2]. However, this decreases with increasing size of the tumour[3]. The majority of driver mutations for the development of RCC metastases develop